DVD Technology-Based System Quickly and Inexpensively Detects SARS-CoV-2 Antigens and Specific Antibodies
By HospiMedica International staff writers Posted on 10 Feb 2021 |
Image: DVD Technology-Based System Quickly and Inexpensively Detects SARS-CoV-2 Antigens and Specific Antibodies (Photo courtesy of Polytechnic University of Valencia)
A new DVD technology-based system quickly and inexpensively detects SARS-CoV-2 antigens and specific antibodies.
Researchers from the Polytechnic University of Valencia (Valencia, Spain) have developed a new system at laboratory scale that allows a rapid, cheap and effective detection of COVID-19. The system consists of a biosensor based on DVD technologies, that detects specific antibodies (G, M and A) and SARS-CoV-2 antigens - differentiating them to those of influenza - in a safe way, in less than 30 minutes, by analyzing serum or saliva samples. The price of the test is estimated at less than two Euros.
Called COMBO-SARS-CoV-2, the system can analyze up to a total of six serum and saliva samples simultaneously, determining type G, M and A antibodies and virus-specific antigens in less than half an hour. When a patient tests positive, the serological and/or saliva sample generates an optical signal that allows the identification of individuals who have suffered or are suffering the infection and establishes the concentration of the specific biomarkers. The COMBO-SARS-CoV-2 system can also be applied to detect other agents with infective capacity such as influenza viruses, adenoviruses and respiratory syncytial virus.
“The developed system will allow a rapid and automated viral diagnosis, at a much lower cost than the kits currently in use. Furthermore, these biosensors will enable a practical and efficient monitoring of the level of neutralizing antibodies once the vaccine is ready,” said Sergi Morais, Professor in the Department of Chemistry.
Related Links:
Polytechnic University of Valencia
Researchers from the Polytechnic University of Valencia (Valencia, Spain) have developed a new system at laboratory scale that allows a rapid, cheap and effective detection of COVID-19. The system consists of a biosensor based on DVD technologies, that detects specific antibodies (G, M and A) and SARS-CoV-2 antigens - differentiating them to those of influenza - in a safe way, in less than 30 minutes, by analyzing serum or saliva samples. The price of the test is estimated at less than two Euros.
Called COMBO-SARS-CoV-2, the system can analyze up to a total of six serum and saliva samples simultaneously, determining type G, M and A antibodies and virus-specific antigens in less than half an hour. When a patient tests positive, the serological and/or saliva sample generates an optical signal that allows the identification of individuals who have suffered or are suffering the infection and establishes the concentration of the specific biomarkers. The COMBO-SARS-CoV-2 system can also be applied to detect other agents with infective capacity such as influenza viruses, adenoviruses and respiratory syncytial virus.
“The developed system will allow a rapid and automated viral diagnosis, at a much lower cost than the kits currently in use. Furthermore, these biosensors will enable a practical and efficient monitoring of the level of neutralizing antibodies once the vaccine is ready,” said Sergi Morais, Professor in the Department of Chemistry.
Related Links:
Polytechnic University of Valencia
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans